L B Harrington1,2, B T Marck3, K L Wiggins4, B McKnight5, S R Heckbert1,6, N F Woods7, A Z LaCroix1,6,8, M Blondon1,9, B M Psaty1,4,6,10, F R Rosendaal11, A M Matsumoto3,12, N L Smith1,6,13. 1. Department of Epidemiology, University of Washington, Seattle, WA, USA. 2. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 3. Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA. 4. Department of Medicine, University of Washington, Seattle, WA, USA. 5. Department of Biostatistics, University of Washington, Seattle, WA, USA. 6. Group Health Research Institute, Seattle, WA, USA. 7. School of Nursing, University of Washington, Seattle, WA, USA. 8. Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA, USA. 9. Division of Angiology and Hemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland. 10. Department of Health Services, University of Washington, Seattle, WA, USA. 11. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. 12. Division of Gerontology & Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA, USA. 13. Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, WA, USA.
Abstract
Essentials Endogenous hormone levels' influence on hemostatic factor levels is not fully characterized. We tested for associations of endogenous hormone with hemostatic factor levels in postmenopause. Estrone levels were inversely associated with the natural anticoagulant, protein S antigen. Dehydroepiandrosterone sulfate levels were inversely associated with thrombin generation. SUMMARY: Background Oral use of exogenous estrogen/progestin alters hemostatic factor levels. The influence of endogenous hormones on these levels is incompletely characterized. Objectives Our study aimed to test whether, among postmenopausal women, high levels of estradiol (E2), estrone (E1), testosterone (T), dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), and androstenedione, and low levels of sex hormone-binding globulin (SHBG), are positively associated with measures of thrombin generation (TG), a normalized activated protein C sensitivity ratio (nAPCsr), and factor VII activity (FVIIc), and negatively associated with antithrombin activity (ATc) and total protein S antigen (PSAg). Methods This Heart and Vascular Health study cross-sectional analysis included 131 postmenopausal women without a prior venous thrombosis who were not currently using hormone therapy. Adjusted mean differences in TG, nAPCsr, FVIIc, ATc and PSAg levels associated with differences in hormone levels were estimated using multiple linear regression. We measured E2, E1, total T, DHEAS, DHEA and androstenedione levels by mass spectrometry, SHBG levels by immunoassay, and calculated the level of free T. Results One picogram per milliliter higher E1 levels were associated with 0.24% lower PSAg levels (95% Confidence Interval [CI]: -0.35, -0.12) and 1 μg mL-1 higher DHEAS levels were associated with 40.8 nm lower TG peak values (95% CI: -59.5, -22.2) and 140.7 nm×min lower TG endogenous thrombin potential (ETP) (95% CI: -212.1, -69.4). After multiple comparisons correction, there was no evidence for other associations. Conclusions As hypothesized, higher E1 levels were associated with lower levels of the natural anticoagulant PSAg. Contrary to hypotheses, higher DHEAS levels were associated with differences in TG peak and ETP that suggest less generation of thrombin.
Essentials Endogenous hormone levels' influence on hemostatic factor levels is not fully characterized. We tested for associations of endogenous hormone with hemostatic factor levels in postmenopause. Estrone levels were inversely associated with the natural anticoagulant, protein S antigen. Dehydroepiandrosterone sulfate levels were inversely associated with thrombin generation. SUMMARY: Background Oral use of exogenous estrogen/progestin alters hemostatic factor levels. The influence of endogenous hormones on these levels is incompletely characterized. Objectives Our study aimed to test whether, among postmenopausal women, high levels of estradiol (E2), estrone (E1), testosterone (T), dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), and androstenedione, and low levels of sex hormone-binding globulin (SHBG), are positively associated with measures of thrombin generation (TG), a normalized activated protein C sensitivity ratio (nAPCsr), and factor VII activity (FVIIc), and negatively associated with antithrombin activity (ATc) and total protein S antigen (PSAg). Methods This Heart and Vascular Health study cross-sectional analysis included 131 postmenopausal women without a prior venous thrombosis who were not currently using hormone therapy. Adjusted mean differences in TG, nAPCsr, FVIIc, ATc and PSAg levels associated with differences in hormone levels were estimated using multiple linear regression. We measured E2, E1, total T, DHEAS, DHEA and androstenedione levels by mass spectrometry, SHBG levels by immunoassay, and calculated the level of free T. Results One picogram per milliliter higher E1 levels were associated with 0.24% lower PSAg levels (95% Confidence Interval [CI]: -0.35, -0.12) and 1 μg mL-1 higher DHEAS levels were associated with 40.8 nm lower TG peak values (95% CI: -59.5, -22.2) and 140.7 nm×min lower TG endogenous thrombin potential (ETP) (95% CI: -212.1, -69.4). After multiple comparisons correction, there was no evidence for other associations. Conclusions As hypothesized, higher E1 levels were associated with lower levels of the natural anticoagulant PSAg. Contrary to hypotheses, higher DHEAS levels were associated with differences in TG peak and ETP that suggest less generation of thrombin.
Authors: A van Hylckama Vlieg; S C Christiansen; R Luddington; S C Cannegieter; F R Rosendaal; T P Baglin Journal: Br J Haematol Date: 2007-09 Impact factor: 6.998
Authors: Guido Tans; Astrid van Hylckama Vlieg; M Christella L G D Thomassen; Joyce Curvers; Rogier M Bertina; Jan Rosing; Frits R Rosendaal Journal: Br J Haematol Date: 2003-08 Impact factor: 6.998
Authors: Shrita M Patel; Sarah J Ratcliffe; Muredach P Reilly; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; Kim Sutton-Tyrrell; John Robbins; Linda P Fried; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2009-10-21 Impact factor: 5.958
Authors: Nicholas L Smith; Marc Blondon; Kerri L Wiggins; Laura B Harrington; Astrid van Hylckama Vlieg; James S Floyd; Melody Hwang; Joshua C Bis; Barbara McKnight; Kenneth M Rice; Thomas Lumley; Frits R Rosendaal; Susan R Heckbert; Bruce M Psaty Journal: JAMA Intern Med Date: 2014-01 Impact factor: 21.873
Authors: Lindsey J Anderson; Dorota Migula; Rebecca Abay; Stephanie Crabtree; Solomon A Graf; Alvin M Matsumoto; Thomas R Chauncey; Jose M Garcia Journal: Andrology Date: 2021-11-25 Impact factor: 3.842
Authors: Nicholas S Roetker; Richard F MacLehose; Ron C Hoogeveen; Christie M Ballantyne; Saonli Basu; Mary Cushman; Aaron R Folsom Journal: Thromb Haemost Date: 2018-10-08 Impact factor: 5.249
Authors: Lindsey J Anderson; Chelsea Yin; Raul Burciaga; Jonathan Lee; Stephanie Crabtree; Dorota Migula; Kelsey Geiss-Wessel; Haiming M Liu; Solomon A Graf; Thomas R Chauncey; Jose M Garcia Journal: Cancers (Basel) Date: 2019-09-04 Impact factor: 6.639
Authors: Luuk J J Scheres; Astrid van Hylckama Vlieg; Bart E P B Ballieux; Bart C J M Fauser; Frits R Rosendaal; Saskia Middeldorp; Suzanne C Cannegieter Journal: J Thromb Haemost Date: 2019-06-04 Impact factor: 5.824